Observ Medical

[TekBot]

Observe Medical ASA: Registration of new share capital

Oslo, 9 January 2025

Reference is made to the stock exchange announcement by Observe Medical ASA
…

Vis børsmeldingen

(“Observe Medical” or the “Company”, OSE ticker: OBSVR) on 7 January 2025,
regarding, inter alia, the resolution of the general meeting to increase the
Company’s share capital by NOK 1.30, through the issue of 5 new shares, each
with a nominal value of NOK 0.26, in order to facilitate for a share
consolidation (reverse share split) in the ratio 15:1.

The share capital increase has now been registered in the Norwegian Register of
Business Enterprises, and the Company’s new share capital is NOK 75,107,806.80,
divided into 288,876,180 shares, each with a nominal value of NOK 0.26.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Observe Medical ASA: Key information relating to share reverse split

Date on which the corporate action was made public: 17 December 2024.

Reverse split ratio: 15 old shares give 1 new share.
…

Vis børsmeldingen

Last day including right: 11 January 2025.

Ex-date: 14 January 2025.

Record date: 15 January 2025.

Date of approval: 7 January 2025.

Other information (optional): A new ISIN number will be issued for the shares.
Further information will be provided in a separate stock exchange announcement.

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on the Oslo Stock Exchange and
Euronext Expand.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Observe Medical ASA: Key information relating to change of ISIN

Issuer: Observe Medical ASA

Previous ISIN: NO0010865009
…

Vis børsmeldingen

New ISIN: NO0013457952

Date of ISIN change: 14 January 2025

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on the Oslo Stock Exchange and
Euronext Expand.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

CORRECTION - Observe Medical ASA: Key information relating to share reverse split

Date on which the corporate action was made public: 17 December 2024.

Reverse split ratio: 15 old shares give 1 new share.
…

Vis børsmeldingen

Last day including right: 13 January 2025.

Ex-date: 14 January 2025.

Record date: 15 January 2025.

Date of approval: 7 January 2025.

Other information (optional): A new ISIN number will be issued for the shares.
Further information will be provided in a separate stock exchange announcement.

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on the Oslo Stock Exchange and
Euronext Expand.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Observe Medical ASA: Ex. reverse share split and new ISIN today

Issuer name: Observe Medical ASA

Ex. date: 14 January 2025
…

Vis børsmeldingen

Type of corporate action: Reverse share split

Other information: Fifteen (15) old shares will give one (1) new share. After
the reverse share split, the share capital is NOK 75,107,806.80 divided into
19,258,412 shares, each with a nominal value of NOK 3.90. The shares in Observe
Medical ASA will be traded with new ISIN from today, 14 January 2025.

New ISIN after reverse share split: NO0013457952.

This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on the Oslo Stock Exchange and
Euronext Expand.

For further information, please contact:

Jørgen Mann, CEO Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialisation of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Observe Medical ASA - Resignation of board member

Oslo, 4 February 2025: Board member Kathrine Elisabeth Gamborg Andreassen has
informed the board of directors of Observe Medical ASA (the “Company” or
“Observe Medical”) that she will resign from the Company’s board of directors,
…

Vis børsmeldingen

effective 5 February 2025, in order to focus on her responsibilities as CEO of
Navamedic ASA.

Following the resignation, the board of directors will continue to constitute a
quorum and is comprised of Terje Bakken (chair), Eskild Endrerud (board member)
and Line Tønnessen (board member).

The appointment of any replacement director is expected to be considered in
relation to the Company’s annual general meeting on 28 May 2025 (the “AGM”). Ms.
Gamborg Andreassen has also informed that she has offered herself for election
to the Company’s nomination committee at the AGM.

For further information, please contact:

Jørgen Mann

CEO

Observe Medical

Mobile: +45 408 67 558

E-mail: jorgen.mann@observemedical.com

Johan Fagerli

CFO

Observe Medical

Mobile: +47 958 12 765

E-mail: johan.fagerli@observemedical.com

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets, and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data
accuracy, and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Observe Medical has received first UnoMeterT SafetiT Plus order from the largest UnoMeterT market and has received repeat orders from several countries.

Oslo, February 28, 2025 - Observe Medical (“the Company” or “Observe Medical”)
has received order from the very important UK market that in 2021 represented
more than 40 mNOK of the total UnoMeterT sales.
…

Vis børsmeldingen

The first significant deliveries of UnoMeterT SafetiT Plus to the distribution
network started in January, with increasing levels in February, and the revenue
on UnoMeterT SafetiT Plus is picking up accordingly.

Observe medical has received repeat orders from 9 countries and positive
feedback on product performance from end-users across many markets.

Jørgen Mann, CEO of Observe Medical, commented, “Our order intake on UnoMeterT
SafetiT Plus continues to increase and we now have UnoMeterT SafetiT Plus in use
on patients in several market with very positive feedback on product
performance. The input we receive from markets confirms that the market
conditions are favorable as no other competitors have been able to replicate the
product performance of UnoMeterT SafetiT Plus. Our distributors are now out
there converting customers and bidding for tenders, and we expect that the
growth in market share will continue in the coming months”.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Observe Medical has received first significant UnoMeterT SafetiT Plus order from Italy

Oslo, 6 March, 2025 -Observe Medical (“the Company” or “Observe Medical”) has
received a significant repeat order from the very important Italian market that
in 2021 represented almost 20 mNOK of the total UnoMeterT annual sales.
…

Vis børsmeldingen

After testing UnoMeterT SafetiT Plus at key customers in the Italian market and
subsequently received very positive feedback on the performance and quality of
the product, the first significant order has been received from the Italian
distributor.

In parallel with the new UnoMeterT SafetiT Plus sales there are already
significant sales of UnoMeterT 500 in the Italian market.

Jørgen Mann, CEO of Observe Medical, commented, “Italy is a very important
market for Observe Medical due to its size and the historic strong position on
the UnoMeterT portfolio. It is great to experience positive customer feedback on
the quality of UnoMeterT SafetiT Plus from an additional market and see that the
customer acceptance means that the first trial orders are now converting into
orders with significant volumes. We have many more significant markets where
trials are ongoing and expect to be able to continue to transfer such trials to
a solid order intake going forward”.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available atwww.observemedical.com.

Kilde

[TekBot]

Observe Medical has received first significant UnoMeter[T] Safeti[T] Plus orders from the Nordic region

Oslo, 13 March, 2025 - Observe Medical (“the Company” or “Observe Medical”) has
received repeat orders and now first significant orders from the Nordic region
where UnoMeter[T] Safeti[T] Plus historically has held a very dominating
…

Vis børsmeldingen

position.

Historically, UnoMeter[T] Safeti[T] Plus has had a dominating market share in
this region consistently exceeding 70% across most markets. The annual sales to
the region has historically been at a level of approximately 15 mNOK, and the re
-introduction of UnoMeter[T] Safeti[T] Plus has been anticipated and now well
received.

Jørgen Mann, CEO of Observe Medical, commented: “The Nordic Region has
historically been dominated by UnoMeter[T] Safeti[T] Plus and the market share
has even reached 100% in some of the markets. We experience that customers have
been reaching out to us for some time now in anticipation for the re-launch of
UnoMeter[T] Safeti[T] Plus and we have seen that tender processes have even been
delayed to make sure UnoMeter[T] Safeti[T] Plus were ready and could be part of
the process. There are several tenders currently active in the region and we
expect to be able to continue the journey of taking back the position as the
preferred solution for urine output measurement”

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available atwww.observemedical.com.

Kilde

[TekBot]

Observe Medical ASA: Interim financial report for second half year 2024

Oslo, March 18, 2025 - Observe Medical (“the Company” or “Observe Medical”)
today releases its results and interim report for the second half and full year
of 2024.
…

Vis børsmeldingen

Business update

2024 marked a pivotal transition toward the launch of UnoMeter Safeti Plus,
historically the most revenue- and profit-generating product in the Convatec
portfolio. Observe Medical is now focused on executing its strategy to reclaim
UnoMeter’s market position. In 2021, the UnoMeter product portfolio generated
approximately NOK 220 million in annual revenue. With an estimated global market
potential of NOK 700 million per year, this presents a substantial growth
opportunity for the Company.

Financial highlights

Observe Medical reported operating revenues of NOK 5.4 million for the second
half of 2024 (H2 2024), reflecting a year-over-year decrease of NOK -10.7
million. For the full year of 2024 (FY 2024) the the Company recorded revenues
of NOK 18.5 million, reflecting a year-over-year decrease of NOK -9.5 million,
primarily driven by the reduction in sales from Nordic distribution portfolio as
the Company transferred certain customer contracts and inventory to another
distributor as part of a strategic restructuring initiative, and other
business (NOK -12.7 million), partly offset by UnoMeterT sales of NOK 11.5
million, reflecting an increase of NOK 3.2 million / +39% year-over-year.

Gross profit in H2 2024 negative of NOK 1.9 million, a decrease of NOK -6.9
million YoY driven by inventory write-down of NOK 3.1 million. Gross profit
adjusted for write-down, NOK 1.2 million. For the full year 2024, the Group
recorded a gross profit adjusted for write-down of NOK 6.2 million, NOK -3.4
million YoY.

Operational expenses of NOK 15.6 million in H2 2024, a reduction of NOK -6.1
million / -28% year-over-year. For the full year the Group had operating
expenses of NOK 33.1 million, a decrease of NOK 15.6 million / -32% year-over
-year

EBITDA adjusted for special items negative NOK 14.3 million, improved by NOK 2.3
million YoY. For the full year of 2024, negative 26.9 million, an improvement of
NOK 12.1 million YoY.

The net finance result was negative NOK 11.2 million vs. negative NOK 5.1
million in H2 2023. For the full year 2024, net finance result was negative NOK
14.4 million vs. negative NOK 10.9 million LY.

The result for H2 2024 was negative NOK 104.5 million vs negative NOK 28.7
million in H2 2023. For the full year 2024 the result was negative NOK 127.0
million, NOK -63.0 million YoY.

The lower result is mainly driven by write-down of goodwill in the second half
year of NOK -69.8 million.

As of December 31, 2024, the company’s equity stood at NOK 24.1 million.

Please find the interim report attatched.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[Savepig]

Egentlig hadde det vært fint om rapporten alltid kom etter stengetid

[TekBot]

Observe Medical ASA: Invitation to investor presentation with trading update 10 April, 2025

Oslo, 19 March 2025 - Observe Medical ASA (OSE: OBSRV) (“the Company” or
“Observe Medical”) will host an investor presentation with trading update
Thursday, 10 April 2025, at 10:00 CET.
…

Vis børsmeldingen

Observe Medical invites investors, analysts, and other stakeholders to an
investor presentation with trading update Thursday 10 April 2025, at 10:00 CET.

The presentation will take place virtually and streamed via webcast at the
following
link: https://channel.royalcast.com/landingpage/hegnarmedia/20250410_3/ (https://
eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2
Flandingpage%2Fhegnarmedia%2F20250410_3%2F&data=05%7C02%7Cjohan.fagerli%40observe
medical.com%7C799b10a0769e4956dc5b08dd66d387b3%7C139dbc03ecf246efb467a338c990a8d6
%7C0%7C0%7C638779780915851860%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlY
iOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sd
ata=4G2vDq%2F6D5U72kR0hQXyQQMWhBwnHp5HN7aO66pBIm8%3D&reserved=0)

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[Quadruple]

Har dette vært grenseløs naivitet eller ren svindel? Jeg har ihvertfall vært grenseløst naiv som har kastet mye penger på bålet.
Selskapet ble etablert for å markedsføre Sippi. “Verdens mest avanserte urinmålesystem”
Men det gikk tregt med salget, og nå blir Sippi knapt nevnt som en mulighet.
Nystad kom inn med Biim (ultralyd) som skulle selge i tusenvis. Det ble med en prøveordre på noen hundre. Nystad skapte store forventninger med sine guidinger om flere hundre millioner på kort sikt.
Nå er det et primitivt urinmålesystem, Unometer, som skal redde selskapet. Her har det også vært snakket om flere hundre millioners marked. Mens det ble solgt for litt over 5 mill. andre halvår 2024. At dette konseptet ble solgt til Observe for småpenger burde vel ringt noen bjeller.
Det har ikke blitt rapportert salgstall i de få meldingene som har vært det siste året.
Hvorfor? Svaret er nok at det bare ville vært pinlig.
Hvorfor har dette gått så galt? Kan man skylde på det vanskelige markedet? For det har langt fra vært lett for selskaper med svak kapitalisering og uetablerte produkter de siste årene.
Nåværende CEO har spådd at 2025 vil bli året da Unometersalget løsner. Eller vil det bli Observ’s siste?

[TekBot]

Observe Medical has entered into agreements in principle with major creditors for a 50% debt reduction

Oslo, April 10[th], 2025 - Observe Medical (“the Company” or “Observe Medical”)
have reached agreements in principle with Convatec and Navamedic to reduce their
debt position from in total NOK 82 million to NOK 41 million, with an adjusted
…

Vis børsmeldingen

payment plan for the remaining debt. Such debt reduction is conditional upon
injection of new equity in the minimum amount of NOK 25 million.

The Company has also been in constructive dialogue with existing shareholders
and new investors who have indicated willingness to contribute equity in an
amount of NOK 25 million, subject to debt reductions being agreed. The
agreements in principle with Convatec and Navamedic will partially cover the
requirement from such investors. Similar negotiations with smaller unsecured
creditors will also be initiated.

It is currently considered likely that an equity raise (if initiated) will take
the form of a private placement and a subsequent repair offering, but the final
transaction structure remains to be determined. Furthermore, final commitments
from the investors who have expressed willingness to participate have not yet
been retained and no assurance can at this stage be given that the contemplated
refinancing will be completed.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Johan Fagerli, CFO of the
Company, on 10 April 2025 at 08:50 hours CET on behalf of the Company.

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Observe Medical - Investor presentation

With reference to today’s webcast, please find enclosed the presentation, also
made available at https://observemedical.com/.

…

Vis børsmeldingen

A recording of the presentation is also available
at: sdk 2.0 player
nColor=da7038,674429 (https://eur03.safelinks.protection.outlook.com/?url=https%3
A%2F%2Fsdk.companywebcast.com%2Fsdk%2Fplayer%2F%3Fid%3Dhegnarmedia_20250410_3%26c
ustomBtnColor%3Dda7038%2C674429&data=05%7C02%7Cjohan.fagerli%40observemedical.com
%7C95918ad22c144110968908dd66e57693%7C139dbc03ecf246efb467a338c990a8d6%7C0%7C0%7C
638779858079459528%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMD
AwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=pG0x7hX
%2BE%2FTF%2BnlsfcETvp0xYQ4Wlv1xEpVJkrVIwa0%3D&reserved=0)

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

Delayed publication of Annual Report 2024

Oslo, April 28, 2025 - Observe Medical (“the Company” or “Observe Medical”)
announces that the publication of its annual report for 2024 is delayed and is
expected to be published no later than 30 May 2025.
…

Vis børsmeldingen

The audit is still ongoing and will not be completed by the 30 April deadline,
resulting in a delay in the publication of the annual report.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

Kilde

[TekBot]

UnoMeter[T] Safeti[T] Plus is now listed with National Health Service (NHS) in England and Observe Medical has received first order from Portugal. KYC completed for largest industrial partner.

Oslo, April 28, 2025 - Observe Medical (“the Company” or “Observe Medical”) is
happy to announce that UnoMeter[TM] Safeti[TM] Plus is now accepted by NHS to be
included on the national listing for England. Also Observe Medical has received
…

Vis børsmeldingen

first order of UnoMeter[TM] Safeti[TM] Plus from Portugal and the journey to
create a strategic partnership with Jiangsu Hongxin Medical Technology Co., Ltd
is taking a step forward with the completion of the KYC process.

The NHS listing will make UnoMeter[TM] Safeti[TM] Plus easily available to all
public hospitals across England which represents a significant opportunity, with
now both UnoMeter[TM] Safeti[TM] Plus and UnoMeter[TM] 500 now represented on
this listing. Also Observe Medical has received first order from Portugal which
means that all products from the Convatec portfolio is now represented in
Portugal.

The Company further announces the completion of the KYC process for Jiangsu
Hongxin Medical Technology Co., Ltd (“JHMT”), which is the Company’s largest
industrial partner within manufacturing and supply paving the way for the
implementation of earlier signed subscription form.

Jørgen Mann, CEO of Observe Medical, commented: “With the first order from
Portugal and orders received from also France and Chile within the last 3 weeks,
we have now received orders from 25 countries with a value above 10 mill NOK.
These countries represent 85% or aprox. NOK 300 million of the historic Convatec
sales to market, in today’s currency and market pricing and this happens only 4
months after we started deliveries of UnoMeter[TM] Safeti[TM] Plus. The NHS
listing means that the English hospitals will have easy access to deliveries of
UnoMeter[TM] Safeti[TM] Plus and it is now up to us and our distributor C&P
Medical to capitalise on this opportunity. We are also very happy to be able to
announce that the process of creating a strategic partnership with our trusted
partner Jiangsu Hongxin Medical Technology Co., Ltd is now moving forward”

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available atwww.observemedical.com.

Kilde

[Quadruple]

“With the first order from
Portugal and orders received from also France and Chile within the last 3 weeks,
we have now received orders from 25 countries with a value above 10 mill NOK.
These countries represent 85% or aprox. NOK 300 million of the historic Convatec
sales to market, in today’s currency and market pricing and this happens only 4
months after we started deliveries of UnoMeter[TM] Safeti[TM] Plus."

[Virage]

Er det samlet eller per ordre?

[Quadruple]

Det er samlet. Men en bra begynnelse hvis det fortsetter.